Alderley Park-based Sutura Therapeutics, has announced it has received the final £7.8 million investment of a seed funding round.
Previous funding had enabled the biopharmaceutical start-up to secure its research facility at the Alderley Park life sciences hub, and the final tranche of seed investment will enable further development its its PeptiGo platform.
The funding round was led by Elevat3 Capital, the venture capital arm of serial entrepreneur and investor Christian Angermayer and his family office, Apeiron Investment Group. Elevat3 has joined Sutura’s Board of Directors.
James Noble, Chairman, said:
“Sutura will enable the development of much needed new medicines to be developed for a wide range of diseases, including those that currently have no effective treatment. We are delighted with the continuous support of Elevat3 and the syndicate of experienced investors. This is a testament to the growth potential of the Company’s technology and the strength of the team.”
Thomas Hanke, Founding Partner at Elevat3 Capital added:
“We were impressed by the Company’s technology platform and look forward to helping Sutura realize the full potential of its ground-breaking approach.”
Sutura Therapeutics is a biopharmaceutical company with a focus on developing next-generation biomolecular medicines. Its PeptiGo platform generates synthetic biomolecules with a rigid peptide domain to help reach targets inaccesbile to other drug delivery methods.
Female Founders Incubator launches at Alderley Park 
Consultation launched on plans for airport-based science, innovation, and manufacturing campus